These brief summaries highlight key developments in COPD and how they are likely to affect patient management in the months and years ahead.
Budesonide-Based Triple Therapy Most Cost-Effective vs Dual Therapy for COPD
A new analysis found triple therapy for COPD, particularly B/G/F, more cost-effective vs dual therapy in terms of exacerbations and quality-adjusted life years.
AstraZeneca at ATS 2024: Look for Late-Breaking Data on Novel Therapeutics for COPD
The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.
Anxiety Raises Risk for Acute Exacerbations in Older Adults with COPD: Daily Dose
Your daily dose of the clinical news you may have missed.
Anxiety Linked to Increased Risk for Acute Exacerbations in Older Adults with COPD
Nearly 20% of an older cohort with COPD reported anxiety that was subsequently associated with more severe symptoms and acute exacerbations.
Decrease in BMI Linked to Increased Risk for Severe Exacerbations, All-Cause Mortality in COPD
Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.
Tezepelumab for COPD Moves into Phase 3 Planning
Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.